Tryptophan hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: Possible link to serotonin deficits and non-motor symptoms in Parkinson's disease

Journal of Neurochemistry

Volumn 116, Issue 3, 2011, Pages 426-437

  Kuhn, Donald M ^a,b   Sykes, Catherine E ^a,b   Geddes, Timothy J ^a,b   Jaunarajs, Karen L Eskow ^c   Bishop, Christopher ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BINGHAMTON UNIVERSITY   (United States)

Author keywords

disulfide cross linking; non motor symptoms; Parkinson's disease; protein aggregation; serotonin neurons; tryptophan hydroxylase 2

Indexed keywords

CYSTEINE; OXYGENASE; SEROTONIN; TYROSINE HYDROXYLASE 2; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CELL INCLUSION; CELL STRAIN HEK293; CONTROLLED STUDY; DISULFIDE BOND; EMBRYO; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; MUTAGENESIS; MUTANT; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FOLDING; SEROTONINERGIC NERVE CELL;

BRAIN; CATALYTIC DOMAIN; CROSS-LINKING REAGENTS; CYSTEINE; DEMENTIA; DISULFIDES; HEK293 CELLS; HUMANS; NEURONS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN FOLDING; SEROTONIN; TRYPTOPHAN HYDROXYLASE;

EID: 78651295081     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.07123.x     Document Type: Article

References (79)

1. Aarsland D., Bronnick K., Alves G., Tysnes O. B., Pedersen K. F., Ehrt U., and, Larsen J. P., (2009) The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 80, 928-930.
2. Ahlskog J. E., (2007) Beating a dead horse: dopamine and Parkinson disease. Neurology 69, 1701-1711.
3. Beekman A. T., Copeland J. R., and, Prince M. J., (1999) Review of community prevalence of depression in later life. Br. J. Psychiatry 174, 307-311.
4. Borah A., and, Mohanakumar K. P., (2007) Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell. Mol. Neurobiol. 27, 985-996.
5. Braak H., Ghebremedhin E., Rub U., Bratzke H., and, Del Tredici K., (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318, 121-134.
6. Bradford M. M., (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
7. Brennan J. P., Wait R., Begum S., Bell J. R., Dunn M. J., and, Eaton P., (2004) Detection and mapping of widespread intermolecular protein disulfide formation during cardiac oxidative stress using proteomics with diagonal electrophoresis. J. Biol. Chem. 279, 41352-41360.
8. Buc-Caron M. H., Launay J. M., Lamblin D., and, Kellermann O., (1990) Serotonin uptake, storage, and synthesis in an immortalized committed cell line derived from mouse teratocarcinoma. Proc. Natl Acad. Sci. USA 87, 1922-1926.
9. Burke W. J., Park D. H., Chung H. D., Marshall G. L., Haring J. H., and, Joh T. H., (1990) Evidence for decreased transport of tryptophan hydroxylase in Alzheimer's disease. Brain Res. 537, 83-87.
10. Cannon J. R., Tapias V., Na H. M., Honick A. S., Drolet R. E., and, Greenamyre J. T., (2009) A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis. 34, 279-290.
11. Carkaci-Salli N., Flanagan J. M., Martz M. K., Salli U., Walther D. J., Bader M., and, Vrana K. E., (2006) Functional domains of human tryptophan hydroxylase 2 (hTPH2). J. Biol. Chem. 281, 28105-28112.
12. Carta M., Carlsson T., Kirik D., and, Bjorklund A., (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130, 1819-1833.
13. Carta M., Carlsson T., Munoz A., Kirik D., and, Bjorklund A., (2008) Involvement of the serotonin system in L-dopa-induced dyskinesias. Parkinsonism Relat. Disord. 14 (Suppl 2), S154-S158.
14. Chaudhuri K. R., Healy D. G., and, Schapira A. H., (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 5, 235-245.
15. Chung K. K., Dawson V. L., and, Dawson T. M., (2001) The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci. 24, S7-S14.
16. Chwastiak L., Ehde D. M., Gibbons L. E., Sullivan M., Bowen J. D., and, Kraft G. H., (2002) Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am. J. Psychiatry 159, 1862-1868.
17. Cicchetti F., Drouin-Ouellet J., and, Gross R. E., (2009) Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?. Trends Pharmacol. Sci. 30, 475-483.
18. Cozzolino M., Amori I., Pesaresi M. G., Ferri A., Nencini M., and, Carri M. T., (2008) Cysteine 111 affects aggregation and cytotoxicity of mutant Cu, Zn-superoxide dismutase associated with familial amyotrophic lateral sclerosis. J. Biol. Chem. 283, 866-874.
19. Cumming R. C., and, Schubert D., (2005) Amyloid-beta induces disulfide bonding and aggregation of GAPDH in Alzheimer's disease. FASEB J. 19, 2060-2062.
20. Cumming R. C., Andon N. L., Haynes P. A., Park M., Fischer W. H., and, Schubert D., (2004) Protein disulfide bond formation in the cytoplasm during oxidative stress. J. Biol. Chem. 279, 21749-21758.
21. De Vos K. J., Grierson A. J., Ackerley S., and, Miller C. C., (2008) Role of axonal transport in neurodegenerative diseases. Annu. Rev. Neurosci. 31, 151-173.
22. Eskow Jaunarajs K. L., Angoa Perez M., Kuhn D. M., and, Bishop C., (2010) Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of L-DOPA treatment. Neurosci. Biobehav. Rev., doi:.
23. Glass C. K., Saijo K., Winner B., Marchetto M. C., and, Gage F. H., (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934.
24. Glickman M. H., and, Ciechanover A., (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373-428.
25. Goldberg A. L., (2003) Protein degradation and protection against misfolded or damaged proteins. Nature 426, 895-899.
26. Halliday G. M., Blumbergs P. C., Cotton R. G., Blessing W. W., and, Geffen L. B., (1990a) Loss of brainstem serotonin-and substance P-containing neurons in Parkinson's disease. Brain Res. 510, 104-107.
27. Halliday G. M., Li Y. W., Blumbergs P. C., Joh T. H., Cotton R. G., Howe P. R., Blessing W. W., and, Geffen L. B., (1990b) Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann. Neurol. 27, 373-385.
28. Hatano T., Kubo S., Sato S., and, Hattori N., (2009) Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease. J. Neurochem. 111, 1075-1093.
29. Horton R. M., Ho S. N., Pullen J. K., Hunt H. D., Cai Z., and, Pease L. R., (1993) Gene splicing by overlap extension. Methods Enzymol. 217, 270-279.
30. Jellinger K. A., (1999) Post mortem studies in Parkinson's disease-is it possible to detect brain areas for specific symptoms? J. Neural Transm. Suppl. 56, 1-29.
31. Joh T. H., Shikimi T., Pickel V. M., and, Reis D. J., (1975) Brain tryptophan hydroxylase: purification of, production of antibodies to, and cellular and ultrastructural localization in serotonergic neurons of rat midbrain. Proc. Natl Acad. Sci. USA 72, 3575-3579.
32. Johansen P. A., Jennings I., Cotton R. G., and, Kuhn D. M., (1995) Tryptophan hydroxylase is phosphorylated by protein kinase A. J. Neurochem. 65, 882-888.
33. Johansen P. A., Jennings I., Cotton R. G., and, Kuhn D. M., (1996) Phosphorylation and activation of tryptophan hydroxylase by exogenous protein kinase A. J. Neurochem. 66, 817-823.
34. Kish S. J., Tong J., Hornykiewicz O., Rajput A., Chang L. J., Guttman M., and, Furukawa Y., (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 131, 120-131.
35. Kosower N. S., and, Kosower E. M., (1995) Diamide: an oxidant probe for thiols. Methods Enzymol. 251, 123-133.
36. Kostic V. S., Djuricic B. M., Covickovic-Sternic N., Bumbasirevic L., Nikolic M., and, Mrsulja B. B., (1987) Depression and Parkinson's disease: possible role of serotonergic mechanisms. J. Neurol. 234, 94-96.
37. Kovacs G. G., Kloppel S., and, Fischer I., et al. (2003) Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders. Neuroreport 14, 73-76.
38. Kuhn D. M., and, Arthur Jr R. E., (1996) Inactivation of brain tryptophan hydroxylase by nitric oxide. J. Neurochem. 67, 1072-1077.
39. Kuhn D. M., and, Arthur Jr. R., (1997) Molecular mechanism of the inactivation of tryptophan hydroxylase by nitric oxide: attack on critical sulfhydryls that spare the enzyme iron center. J. Neurosci. 17, 7245-7251.
40. Kuhn D. M., and, Arthur R. Jr, (1998) Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein: possible endogenous toxin to serotonin neurons. J. Neurosci. 18, 7111-7117.
41. Kuhn D. M., and, Arthur R. E., (1999) L-DOPA-quinone inactivates tryptophan hydroxylase and converts the enzyme to a redox-cycling quinoprotein. Brain Res. Mol. Brain Res. 73, 78-84.
42. Kuhn D. M., and, Geddes T. J., (1999) Peroxynitrite inactivates tryptophan hydroxylase via sulfhydryl oxidation. Coincident nitration of enzyme tyrosyl residues has minimal impact on catalytic activity. J. Biol. Chem. 274, 29726-29732.
43. Kuhn D. M., Ruskin B., and, Lovenberg W., (1980) Tryptophan hydroxylase. The role of oxygen, iron, and sulfhydryl groups as determinants of stability and catalytic activity. J. Biol. Chem. 255, 4137-4143.
44. Kuhn D. M., Sadidi M., Liu X., Kreipke C., Geddes T., Borges C., and, Watson J. T., (2002) Peroxynitrite-induced nitration of tyrosine hydroxylase: identification of tyrosines 423, 428, and 432 as sites of modification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry and tyrosine-scanning mutagenesis. J. Biol. Chem. 277, 14336-14342.
45. Kuhn D. M., Sakowski S. A., Geddes T. J., Wilkerson C., and, Haycock J. W., (2007) Phosphorylation and activation of tryptophan hydroxylase 2: identification of serine-19 as the substrate site for calcium, calmodulin-dependent protein kinase II. J. Neurochem. 103, 1567-1573.
46. Lee H. J., and, Lee S. J., (2002) Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem. 277, 48976-48983.
47. Maruyama W., Naoi M., Takahashi A., Watanabe H., Konagaya Y., Mokuno K., Hasegawa S., and, Nakahara D., (1992) The mechanism of perturbation in monoamine metabolism by L-dopa therapy: in vivo and in vitro studies. J. Neural Transm. Gen. Sect. 90, 183-197.
48. Mayeux R., Stern Y., Cote L., and, Williams J. B., (1984) Altered serotonin metabolism in depressed patients with parkinson's disease. Neurology 34, 642-646.
49. McKinlay A., Grace R. C., Dalrymple-Alford J. C., Anderson T., Fink J., and, Roger D., (2008) A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. Parkinsonism Relat. Disord. 14, 37-42.
50. Mockus S. M., Kumer S. C., and, Vrana K. E., (1997) Carboxyl terminal deletion analysis of tryptophan hydroxylase. Biochim. Biophys. Acta 1342, 132-140.
51. Murai T., Muller U., Werheid K., Sorger D., Reuter M., Becker T., von Cramon D. Y., and, Barthel H., (2001) In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J. Neuropsychiatry Clin. Neurosci. 13, 222-228.
52. Navailles S., Benazzouz A., Bioulac B., Gross C., and, De Deurwaerdere P., (2010a) High-frequency stimulation of the subthalamic nucleus and L-3, 4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J. Neurosci. 30, 2356-2364.
53. Navailles S., Bioulac B., Gross C., and, De Deurwaerdere P., (2010b) Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol. Dis. 38, 136-143.
54. Nilsson F. M., Kessing L. V., and, Bolwig T. G., (2001) Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatr. Scand. 104, 380-386.
55. Niwa J., Yamada S., Ishigaki S., Sone J., Takahashi M., Katsuno M., Tanaka F., Doyu M., and, Sobue G., (2007) Disulfide bond mediates aggregation, toxicity, and ubiquitylation of familial amyotrophic lateral sclerosis-linked mutant SOD1. J. Biol. Chem. 282, 28087-28095.
56. Obeso J. A., Rodriguez-Oroz M. C., and, Goetz C. G., et al. (2010) Missing pieces in the Parkinson's disease puzzle. Nat. Med. 16, 653-661.
57. Paulus W., and, Jellinger K., (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. J. Neuropathol. Exp. Neurol. 50, 743-755.
58. Pickel V. M., Joh T. H., and, Reis D. J., (1976) Monoamine-synthesizing enzymes in central dopaminergic, noradrenergic and serotonergic neurons. Immunocytochemical localization by light and electron microscopy. J. Histochem. Cytochem. 24, 792-306.
59. Ren Y., and, Feng J., (2007) Rotenone selectively kills serotonergic neurons through a microtubule-dependent mechanism. J. Neurochem. 103, 303-311.
60. Ressler K. J., and, Nemeroff C. B., (2000) Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress. Anxiety 12 (Suppl 1), 2-19.
61. Sakowski S. A., Geddes T. J., and, Kuhn D. M., (2006a) Mouse tryptophan hydroxylase isoform 2 and the role of proline 447 in enzyme function. J. Neurochem. 96, 758-765.
62. Sakowski S. A., Geddes T. J., Thomas D. M., Levi E., Hatfield J. S., and, Kuhn D. M., (2006b) Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. Brain Res. 1085, 11-18.
63. Sawada M., Nagatsu T., Nagatsu I., Ito K., Iizuka R., Kondo T., and, Narabayashi H., (1985) Tryptophan hydroxylase activity in the brains of controls and parkinsonian patients. J. Neural Transm. 62, 107-115.
64. Scatton B., Javoy-Agid F., Rouquier L., Dubois B., and, Agid Y., (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 275, 321-328.
65. Scherzinger E., Lurz R., and, Turmaine M., et al. (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549-558.
66. Schlehe J. S., Lutz A. K., Pilsl A., Lammermann K., Grgur K., Henn I. H., Tatzelt J., and, Winklhofer K. F., (2008) Aberrant folding of pathogenic parkin mutants: aggregation versus degradation. J. Biol. Chem. 283, 13771-13779.
67. Schrag A., (2006) Quality of life and depression in Parkinson's disease. J. Neurol. Sci. 248, 151-157.
68. Schuurman A. G., van den Akker M., Ensinck K. T., Metsemakers J. F., Knottnerus J. A., Leentjens A. F., and, Buntinx F., (2002) Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 58, 1501-1504.
69. Simuni T., and, Sethi K., (2008) Nonmotor manifestations of Parkinson's disease. Ann. Neurol. 64 (Suppl 2), S65-S80.
70. Sitia R., and, Molteni S. N., (2004) Stress, protein (mis)folding, and signaling: the redox connection. Sci. STKE 239, 1-5.
71. Tan J. M., Wong E. S., and, Lim K. L., (2009) Protein misfolding and aggregation in Parkinson's disease. Antioxid. Redox Signal. 11, 2119-2134.
72. Taylor T. N., Caudle W. M., Shepherd K. R., Noorian A., Jackson C. R., Iuvone P. M., Weinshenker D., Greene J. G., and, Miller G. W., (2009) Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 29, 8103-8113.
73. Tenner K., Walther D., and, Bader M., (2007) Influence of human tryptophan hydroxylase 2 N-and C-terminus on enzymatic activity and oligomerization. J. Neurochem. 102, 1887-1894.
74. Vrana K. E., (1999) How the regulatory and catalytic domains get together. Nat. Struct. Biol. 6, 401-402.
75. Wang G., Hong Z., and, Cheng Q., et al. (2009) Validation of the Chinese non-motor symptoms scale for Parkinson's disease: results from a Chinese pilot study. Clin. Neurol. Neurosurg. 111, 523-526.
76. White L. A., and, Whittemore S. R., (1992) Immortalization of raphe neurons: an approach to neuronal function in vitro and in vivo. J. Chem. Neuroanat. 5, 327-330.
77. Winklhofer K. F., Tatzelt J., and, Haass C., (2008) The two faces of protein misfolding: gain-and loss-of-function in neurodegenerative diseases. EMBO J. 27, 336-349.
78. Wragg R. E., and, Jeste D. V., (1989) Overview of depression and psychosis in Alzheimer's disease. Am. J. Psychiatry 146, 577-587.
79. Yao Z., and, Wood N. W., (2009) Cell death pathways in Parkinson's disease: role of mitochondria. Antioxid. Redox Signal. 11, 2135-2149.